Abstract 3328
Background
SHR-1210 is a humanized anti–PD-1 antibody, with immunoglobulin gamma 4 (IgG4) as heavy chain and immunoglobulin kappa (IgK) as light chain expressed in the supernatant of a Chinese hamster ovary (CHO) stable cell line. Antitumor activity data for the ongoing clinical studies of SHR-1210 are currently being evaluated. SHR-1210 is currently being tested in 15 studies in advanced malignancies: 4 in advanced solid tumors, 3 in NSCLC, 2 in hepatocellular cancer (HCC; including 1 in HCC or gastric cancer [GC]), 2 in esophageal cancer (EC), 1 in melanoma, 1 in nasopharyngeal cancer (NPC), 1 in primary liver cancer (PLC), and 1 in classic Hodgkin lymphoma (cHL). Since 22 MAY 2017, 395 patients have been enrolled in this trial.
Trial design
In this trial, 412 patients will be randomly assigned in a 1:1 ratio, to receive either carboplatin-pemetrexed chemotherapy,OR receive SHR-1210 combined with carboplatin-pemetrexed chemotherapy. Randomization will be stratified according to gender and smoking history. All the patients will receive carboplatin(area under the curve 5) plus pemetrexed(500 mg/m2), all administered as IV infusion on Day 1 of each 3-week cycle for 4 or 6 cycles of the investigator's choice, followed by pemetrexed(500 mg/m2) every 3 weeks(Q3W) maintenance for the remainder of the study. Patients assigned to the SHR-1210 combined with chemotherapy arm, will additionally receive SHR-1210(200mg) administered as IV infusion on Day 1 of each 3-week cycle, for up to 35 cycles. Patients assigned to the chemotherapy arm will have the opportunity to crossover to receive SHR-1210(200mg) monotherapy every 3 weeks(Q3W) once they experience progression of disease (PD) defined by RECIST 1.1 and meet all crossover criteria.
Clinical trial identification
NCT03134872.
Legal entity responsible for the study
Jiangsu HengRui Medicine Co., Ltd.
Funding
Jiangsu HengRui Medicine Co., Ltd.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4293 - Prediction of response to vemurafenib in BRAF V600E mutant cancers based on a network approach
Presenter: Rosa Falcone
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4384 - Improving value for cancer patients: A European study of outcomes in practice
Presenter: Rishi Hazarika
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5485 - High-throughput screening of new drugs targeting lung CSCs
Presenter: Héctor Amado Labrador
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4218 - RING observational trial to compare T790M mutation testing in blood by different methodologies
Presenter: Beatriz Garcia-Pelaez
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2775 - Indicators of non-participation in cervical cancer screening: Results from the EDIFICE 6 survey
Presenter: Thibault de La Motte Rouge
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5852 - Tolerance and efficacy of immune-checkpoint inhibitors for cancer in people living with HIV (PWHIV)
Presenter: Aurélien Gobert
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
819 - Effects of physical exercise in non-operable lung cancer patients undergoing palliative treatment
Presenter: Joachim Wiskemann
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract